Real-world effectiveness of adjuvanted RSVPreF3 vaccination in the prevention of RSV-related hospitalization among US adults aged ≥60 years
Chest
•
July 09, 2026
RSVPreF3 reduces RSV hospitalizations
The immune-boosted RSVPreF3 vaccine was linked to far fewer RSV-related hospitalizations. *Retrospective matched cohort study; Level 3 (OCEBM).
- Level of evidence
- Level 3 (OCEBM)
- DocG quality score
- 7.2 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
